Integrating Clinical Portfolios a Vexing, Critical Challenge Facing Merging Drug Giants to be Addressed at Conference on May 15-16 in Philadelphia

Apr 11, 2001, 01:00 ET from Strategic Research Institute

    NEW YORK, April 11 /PRNewswire/ -- Portfolio managers today face the
 especially daunting task of integrating huge clinical portfolios as the
 pharmaceutical industry continues to consolidate, announces Strategic Research
 Institute.
     A conference on Rx & Biotech Portfolio Management to take place in
 Philadelphia on May 15-16, will address this high-stakes issue with
 presentations by major pharmaceutical & biotech companies on its experiences.
     The purpose is to generate take-away points to guide their fellow
 portfolio managers both actively and prospectively as the spate of mergers and
 acquisitions is in full swing and likely to continue.
     At stake are billions of dollars in potential drugs moving through
 clinical trials.  The task of making the right decisions in keeping, or
 shedding drug candidates is exacerbated by the sheer size of the merging
 companies and their rich piplines.
     This timely meeting could not have come at a better moment -- in the wake
 of several recent mergers and at the cusp of new ones.
     To register for the conference and/or to request additional information,
 contact Glenn Pascual of Strategic Research Institute at
 gpascual@srinstitute.com (include name, corporate title, company and
 mailing/email address) or call Mr. Pascual at 212-967.0095, 245.
 
 

SOURCE Strategic Research Institute
    NEW YORK, April 11 /PRNewswire/ -- Portfolio managers today face the
 especially daunting task of integrating huge clinical portfolios as the
 pharmaceutical industry continues to consolidate, announces Strategic Research
 Institute.
     A conference on Rx & Biotech Portfolio Management to take place in
 Philadelphia on May 15-16, will address this high-stakes issue with
 presentations by major pharmaceutical & biotech companies on its experiences.
     The purpose is to generate take-away points to guide their fellow
 portfolio managers both actively and prospectively as the spate of mergers and
 acquisitions is in full swing and likely to continue.
     At stake are billions of dollars in potential drugs moving through
 clinical trials.  The task of making the right decisions in keeping, or
 shedding drug candidates is exacerbated by the sheer size of the merging
 companies and their rich piplines.
     This timely meeting could not have come at a better moment -- in the wake
 of several recent mergers and at the cusp of new ones.
     To register for the conference and/or to request additional information,
 contact Glenn Pascual of Strategic Research Institute at
 gpascual@srinstitute.com (include name, corporate title, company and
 mailing/email address) or call Mr. Pascual at 212-967.0095, 245.
 
 SOURCE  Strategic Research Institute